文献速递妇科肿瘤

芦卡帕利用于铂敏感复发性卵巢癌维持治疗:3期随机安慰剂对照ARIEL3试验最终结果

Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial.
PubMed 文献 · Eur J Cancer · 2025-06-17

ARIEL3最终分析显示,在铂敏感复发性卵巢癌患者中,芦卡帕利维持治疗与安慰剂相比总生存相似(BRCA突变人群45.9 vs 47.8个月,HR 0.83,95%CI 0.58-1.19),无总生存获益;无进展生存获益维持至后续治疗线,安全性与此前报告一致。

要点

  • BRCA突变人群总生存芦卡帕利45.9个月 vs 安慰剂47.8个月(HR 0.83,95%CI 0.58-1.19)。
  • BRCA突变人群PFS2芦卡帕利26.1个月 vs 安慰剂18.4个月(HR 0.67,95%CI 0.48-0.94)。
  • 骨髓增生异常综合征和/或急性髓系白血病发生率芦卡帕利4% vs 安慰剂3%。

核心结论

  • 总生存在两治疗组间相似,芦卡帕利的无进展生存获益维持至后续治疗线,这些数据支持芦卡帕利用于复发性卵巢癌维持治疗。

研究设计与样本

  • ARIEL3为3期随机安慰剂对照试验,患者按2:1随机接受芦卡帕利600 mg每日两次(n=375)或安慰剂(n=189),中位随访77.0个月,数据截止日期为2022年4月4日,在BRCA突变、同源重组缺陷(HRD)和意向治疗(ITT)三个嵌套人群中分析总生存和长期随访疗效。

主要发现

  • BRCA突变人群从随机化起经化疗后中位总生存芦卡帕利45.9个月 vs 安慰剂47.8个月(HR 0.83,95%CI 0.58-1.19)。
  • HRD和ITT人群中未发现芦卡帕利的总生存获益。
  • BRCA突变人群中位PFS2芦卡帕利26.1个月 vs 安慰剂18.4个月(HR 0.67,95%CI 0.48-0.94)。
  • HRD和ITT人群中芦卡帕利较安慰剂在数值上改善PFS2和其他长期随访结局。
  • 安全性与此前报告一致,骨髓增生异常综合征和/或急性髓系白血病在芦卡帕利组和安慰剂组的发生率分别为4%和3%。

关键数值与推荐

  • BRCA突变人群总生存:芦卡帕利45.9个月 vs 安慰剂47.8个月(HR 0.83,95%CI 0.58-1.19)。
  • BRCA突变人群PFS2:芦卡帕利26.1个月 vs 安慰剂18.4个月(HR 0.67,95%CI 0.48-0.94)。
  • 安慰剂组168例患者接受后续治疗,其中77例(46%)接受了含聚(ADP-核糖)聚合酶抑制剂的治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In ARIEL3, rucaparib maintenance significantly improved progression-free survival (PFS; primary endpoint) and long-term follow-up (LTFU) outcomes (including PFS2: time to disease progression on subsequent therapy or death) versus placebo in patients with recurrent, platinum-sensitive ovarian cancer. Here we report the final analysis of overall survival (OS; key secondary endpoint), LTFU outcomes, and safety. METHODS: OS and updated LTFU efficacy outcomes were analyzed (data cutoff date: April 4, 2022) across three nested populations (BRCA-mutated, homologous recombination deficient [HRD], and intention to treat [ITT]). RESULTS: Patients were randomized 2:1 to rucaparib (600 mg BID; n = 375) or placebo (n = 189). Median follow-up was 77.0 months. 168 patients in the placebo arm received subsequent treatment; of these, 77 (46 %) received a poly(ADP-ribose) polymerase inhibitor-containing treatment. Median OS from randomization post chemotherapy for rucaparib vs placebo was 45.9 vs 47.8 months (HR 0.83, 95 % CI 0.58-1.19) for the BRCA-mutated population; no OS benefit was found with rucaparib in the HRD and ITT populations. Median PFS2 for rucaparib vs placebo was 26.1 vs 18.4 months (HR 0.67, 95 % CI 0.48-0.94) for the BRCA-mutated population. Rucaparib numerically improved PFS2 and other LTFU outcomes versus placebo in the HRD and ITT populations. Safety was consistent with prior reports; myelodysplastic syndrome and/or acute myeloid leukemia occurred in 4 % and 3 % of patients in the rucaparib and placebo arms, respectively. CONCLUSIONS: OS was similar between treatment arms. PFS benefit with rucaparib was maintained through the subsequent therapy line. These data support rucaparib as maintenance treatment for recurrent ovarian carcinoma.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ledermann JA, Oza AM, Lorusso D, et al. Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial. Eur J Cancer. 2025. PMID: 40580808. doi:10.1016/j.ejca.2025.115584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。